vimarsana.com
Home
Live Updates
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
Press release content from Accesswire. The AP news staff was not involved in its creation.
Related Keywords
China ,
Germany ,
Japan ,
United States ,
Munich ,
Bayern ,
Planegg ,
America ,
American ,
Semin Nephrol ,
Thomas Biegi ,
Julia Neugebauer ,
Asia Pacific ,
Myles Clouston ,
Mikhail Akimov ,
Jeanette Bressi ,
Global Head Drug Development At Morphosys ,
Janssen Biotech Inc ,
Drug Administration ,
Single Center ,
Morphosys Group ,
Constellation Pharmaceuticals Inc ,
Janssen Research Development ,
Morphosys Us Inc ,
Distribution Services ,
Exchange Commission ,
Us Communications ,
Senior Vice President ,
Global Head Drug Development ,
North America ,
I Mab Biopharma ,
Janssen Research ,
Janssen Biotech ,
Constellation Pharmaceuticals ,
Morphosy Annual Report ,
Res Clin ,
Iga Nephropathy ,
Clinj Am Soc ,
Containing Immune Complexes ,
Year Analysis ,
Corporate News ,
Regulatory Announcements ,
Business ,
Health ,
Accesswire ,
Clinical Trials ,
Morphosys Ag ,